Valuation: Compass Therapeutics, Inc.

Market Cap 378M 331M 308M 283M 533M 36.49B 541M 3.66B 1.43B 17.86B 1.42B 1.39B 61.69B P/E 2026 *
-4.82x
P/E 2027 * -4.52x
Enterprise Value 228M 200M 186M 171M 321M 22.02B 326M 2.21B 865M 10.77B 857M 838M 37.22B EV / Sales 2026 *
-111x
EV / Sales 2027 * 9.74x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day-4.05%
1 week-6.85%
Current month-6.85%
1 month+0.99%
3 months-61.07%
6 months-65.42%
Current year-62.01%
1 week 2
Extreme 2
2.15
1 month 2
Extreme 2
2.36
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 50 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
4/29/26 Buy

General Counsel

25,000 0.0139%
4/29/26 Buy

Controller/Auditor

15,000 0.0083%
2/8/26 Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
-2.86%-6.85%-33.55%-22.73% 378M
-0.43%-1.26%+52.13%+85.69% 55.57B
-0.24%-0.37%+57.02%+54.21% 54.26B
-0.54%+1.58%-15.68%-15.43% 23.35B
-1.82%-3.15%+3.76%+405.88% 23.54B
+0.05%+1.68%+38.71%-4.57% 20.32B
+3.16%+2.74%+37.33%-31.36% 17.36B
+1.08%+3.77%+36.92%+593.96% 15.59B
+0.43%-1.67%+166.53%+299.61% 14.96B
-2.03%-1.42%+24.22%+179.23% 14.11B
Average -0.44%-0.62%+36.74%+154.45% 23.94B
Weighted average by Cap. -0.18%-0.24%+44.03%+135.84%

Financials

2026 *2027 *
Net sales -2.06M -1.8M -1.67M -1.54M -2.9M -199M -2.94M -19.93M -7.8M -97.13M -7.72M -7.56M -336M 25.27M 22.14M 20.55M 18.89M 35.59M 2.44B 36.11M 245M 95.84M 1.19B 94.86M 92.81M 4.12B
Net income -82.44M -72.23M -67.06M -61.62M -116M -7.95B -118M -799M -313M -3.89B -309M -303M -13.45B -89.57M -78.48M -72.86M -66.95M -126M -8.64B -128M -868M -340M -4.23B -336M -329M -14.61B
Net Debt -150M -131M -122M -112M -211M -14.47B -214M -1.45B -569M -7.08B -563M -551M -24.47B -132M -116M -107M -98.66M -186M -12.74B -189M -1.28B -501M -6.23B -496M -485M -21.53B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
26-07-22 US$2.040 -2.86% 1,769,998
26-07-21 US$2.100 +3.96% 1,620,718
26-07-20 US$2.020 -1.46% 1,906,655
26-07-17 US$2.050 -2.38% 2,143,118
26-07-16 US$2.100 -1.87% 1,760,205
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.100USD
Average target price
8.500USD
Spread / Average Target
+304.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock